Novartis AG ADR Stock
€106.00
Your prediction
Novartis AG ADR Stock
Pros and Cons of Novartis AG ADR in the next few years
Pros
Cons
Performance of Novartis AG ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novartis AG ADR | -0.470% | 1.435% | 6.855% | 12.051% | 16.228% | 32.832% | 33.535% |
| Roche Holding AG ADR | -1.240% | 1.413% | 5.881% | 8.516% | 15.238% | -13.081% | - |
| Bayer AG ADR | 3.700% | -2.098% | 6.061% | -43.548% | -18.605% | -40.678% | -58.084% |
| Novo Nordisk A/S ADR | -1.210% | 0.000% | -0.407% | -30.000% | 30.597% | 35.809% | 160.638% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon reviewing the financial statements of Novartis (NASDAQ: NVS), a prominent player in the pharmaceutical industry, the general impression suggests that the company maintains a solid financial standing. With substantial total assets, a strong revenue base, and a broad diversification through various investments, Novartis appears to be a robust organization in terms of financial health.
Cash Position: Novartis has maintained a considerable cash position in recent years, end of 2022 standing at $7.52B. A strong liquidity profile allows the company to invest in research and development or pursue mergers and acquisitions to drive future growth.
Increasing Revenue: The total revenue increased from $49.9B in 2020 to $52.9B in 2021 and further up to $58.2B in 2022. This growth suggests that the company is effectively generating business, increasing market share, and expanding its product portfolio.
Comments
News
Pharma Leader Beats on Earnings, But Shares Fall
Novartis (NYSE:NVS) is the seventh largest pharmaceutical company in the world, and is based in Switzerland. The firm reported Q2 2024 financial results on Jul. 18, 2024. The company is performing
Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
Novartis Ag (NYSE: NVS)Q2 2024 Earnings CallJul 18, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Why Novartis Stock Is Down Today Despite Topping Q2 Estimates
By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than